Pluristem prices $32m offering to progress stem cell therapies
This article was originally published in Clinica
Allogeneic stem cell therapy developer Pluristem Therapeutics has priced a stock offering to raise gross proceeds of $32 million which will go towards financing research and development, including clinical trials of its cell-based vascular disease treatment. The company will offer eight million units – each unit consisting of one share of common stock and a warrant to purchase 35% of one share - at $4 per unit.
You may also be interested in...
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.
Public Company Edition: Three companies postponed or withdrew their offerings, but drug developers continue to pursue IPOs. Also, Biocon, BMS and Epizyme raised money through new debt, Five Prime capitalized on positive data and Synthetic Biologic engaged a strategic advisor.